HER3 mediates acquired resistance to HER2-targeted therapy in esophageal adenocarcinoma

被引：1
|
作者：
Ebbing, Eva A. [1 ]
Medema, Jan Paul [1 ]
Meijer, Sybren L. [1 ]
Krishnadath, Kausilia K. [1 ]
Henegouwen, Mark I. van Berge [1 ]
Bijlsma, Maarten F. [1 ]
van Laarhoven, Hanneke W. M. [1 ]
机构：
[1] AMC, Amsterdam, Netherlands
来源：
CANCER RESEARCH | 2015年 / 75卷
关键词：
D O I：
10.1158/1538-7445.AM2015-350
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
350
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Acquired Resistance to HER2-Targeted Therapies Creates Vulnerability to ATP Synthase Inhibition
    Gale, Molly
    Li, Yao
    Cao, Jian
    Liu, Zongzhi Zachary
    Holmbeck, Marissa A.
    Zhang, Meiling
    Lang, Sabine M.
    Wu, Lizhen
    Carmo, Mariana
    Gupta, Swati
    Aoshima, Keisuke
    DiGiovanna, Michael P.
    Stern, David F.
    Rimm, David L.
    Shadel, Gerald S.
    Chen, Xiang
    Yan, Qin
    CANCER RESEARCH, 2020, 80 (03) : 524 - 535
  • [22] Novel HER2-targeted therapy to overcome trastuzumab resistance in HER2-amplified gastric cancer
    Park, Juin
    Kang, Sun Kyoung
    Kwon, Woo Sun
    Jeong, Inhye
    Kim, Tae Soo
    Yu, Seo Young
    Cho, Sang Woo
    Chung, Hyun Cheol
    Rha, Sun Young
    SCIENTIFIC REPORTS, 2023, 13 (01)
  • [23] Novel HER2-targeted therapy to overcome trastuzumab resistance in HER2-amplified gastric cancer
    Juin Park
    Sun Kyoung Kang
    Woo Sun Kwon
    Inhye Jeong
    Tae Soo Kim
    Seo Young Yu
    Sang Woo Cho
    Hyun Cheol Chung
    Sun Young Rha
    Scientific Reports, 13
  • [24] JNK Pathway Activation Modulates Acquired Resistance to EGFR/HER2-Targeted Therapies
    Manole, Simin
    Richards, Edward J.
    Meyer, Aaron S.
    CANCER RESEARCH, 2016, 76 (18) : 5219 - 5228
  • [25] HER-2/neu Gene Amplification in Relation to Expression of HER2 and HER3 Proteins in Patients With Esophageal Adenocarcinoma
    Yoon, Harry H.
    Sukov, William R.
    Shi, Qian
    Sattler, Christopher A.
    Wiktor, Anne E.
    Diasio, Robert B.
    Wu, Tsung-Teh
    Jenkins, Robert B.
    Sinicrope, Frank A.
    CANCER, 2014, 120 (03) : 415 - 424
  • [26] HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2+ Breast Cancer
    Xu, Xiaowei
    De Angelis, Carmine
    Burke, Kathleen A.
    Nardone, Agostina
    Hu, Huizhong
    Qin, Lanfang
    Veeraraghavan, Jamunarani
    Sethunath, Vidyalakshmi
    Heiser, Laura M.
    Wang, Nicholas
    Ng, Charlotte K. Y.
    Chen, Edward S.
    Renwick, Alexander
    Wang, Tao
    Nanda, Sarmistha
    Shea, Martin
    Mitchell, Tamika
    Rajendran, Mahitha
    Waters, Ian
    Zabransky, Daniel J.
    Scott, Kenneth L.
    Gutierrez, Carolina
    Nagi, Chandandeep
    Geyer, Felipe C.
    Chamness, Gary C.
    Park, Ben H.
    Shaw, Chad A.
    Hilsenbeck, Susan G.
    Rimawi, Mothaffar F.
    Gray, Joe W.
    Weigelt, Britta
    Reis-Filho, Jorge S.
    Osborne, C. Kent
    Schiff, Rachel
    CLINICAL CANCER RESEARCH, 2017, 23 (17) : 5123 - 5134
  • [27] Yes1 is the key molecule for resistance to HER2-targeted therapy
    Takeda, Tatsuaki
    Yamamoto, Hiromasa
    Suzawa, Ken
    Tomida, Shuta
    Namba, Kei
    Watanabe, Mototsugu
    Shien, Kazuhiko
    Soh, Junichi
    Tsukuda, Kazunori
    Toyooka, Shinichi
    CANCER SCIENCE, 2018, 109 : 1146 - 1146
  • [28] Detailed curriculum vitae of HER2-targeted therapy
    Zhang, Xiao-Nan
    Gao, Ya
    Zhang, Xi-Ya
    Guo, Ning-Jie
    Hou, Wen-Qing
    Wang, Shu-Wu
    Zheng, Yi-Chao
    Wang, Ning
    Liu, Hong -Min
    Wang, Bo
    PHARMACOLOGY & THERAPEUTICS, 2023, 245
  • [29] HER2-targeted therapy-antibodies and beyond
    Fehm, Tanja
    Mueller, Volkmar
    GYNAKOLOGE, 2021, 54 (05): : 320 - 328
  • [30] Mechanisms of Resistance to HER2-Targeted Therapies in HER2-positive Breast Cancer
    Veeraraghavan, Jamunarani
    Liao, Fu-Tien
    Qin, Lanfang
    Gordon, Tia
    Raghavan, Alekya
    Sabotta, Caroline
    Kaplan, Rachel
    Gutierrez, Carolina
    Osborne, C. Kent
    Rimawi, Mothaffar F.
    Schiff, Rachel
    CANCER RESEARCH, 2024, 84 (03)
12345